Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax
- Conditions
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT03343678
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
- Conditions
- Interventions
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 590
- Registration Number
- NCT03336333
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Augusta University, Augusta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 82
- Registration Number
- NCT03319901
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Intermountain LDS Hospital, Salt Lake City, Utah, United States
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 156
- Registration Number
- NCT03314181
- Locations
- 🇦🇺
Eastern Health /ID# 165850, Box Hill, Victoria, Australia
🇨🇦Cross Cancer Institute /ID# 203114, Edmonton, Alberta, Canada
🇯🇵Kameda General Hospital /ID# 225246, Kamogawa-shi, Chiba, Japan
A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT03312530
- Locations
- 🇫🇷
CHU - Hôtel Dieu hematolgie clinique, Nantes, France
🇨🇿Fakultni nemocnice Ostrava; Klinika hematoonkologie, Ostrava, Czechia
🇨🇿Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika, Brno, Czechia
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 136
- Registration Number
- NCT03276468
- Locations
- 🇫🇷
CHU de Caen, Caen, France
🇫🇷CHRU de Lille, Lille, France
🇫🇷CHU d'Angers, Angers, France
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6
- Conditions
- Interventions
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 39
- Registration Number
- NCT03255096
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Stanford Cancer Center, Stanford, California, United States
🇦🇺Peter MacCallum Cancer Centre-East Melbourne, Melbourne, Victoria, Australia
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
- Conditions
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 143
- Registration Number
- NCT03236857
- Locations
- 🇫🇷
AP-HM - Hopital de la Timone /ID# 161465, Marseille CEDEX 05, Bouches-du-Rhone, France
🇺🇸Memorial Sloan Kettering Cancer Center-Koch Center /ID# 163444, New York, New York, United States
🇫🇷Robert Debre Hopital, FR /ID# 161464, Paris, France
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 75
- Registration Number
- NCT03226418
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 145
- Registration Number
- NCT03223610
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.